Logo image of ARBS.MI

ARTERRA BIOSCIENCE SPA (ARBS.MI) Stock Fundamental Analysis

BIT:ARBS - Euronext Milan - IT0005386369 - Common Stock - Currency: EUR

2.24  -0.12 (-5.08%)

Fundamental Rating

3

Overall ARBS gets a fundamental rating of 3 out of 10. We evaluated ARBS against 0 industry peers in the Unkown industry. ARBS has a great financial health rating, but its profitability evaluates not so good. ARBS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARBS had positive earnings in the past year.
Each year in the past 5 years ARBS has been profitable.
ARBS had a positive operating cash flow in each of the past 5 years.
ARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M

1.2 Ratios

Industry RankSector Rank
ROA 10.72%
ROE 12.68%
ROIC 9.1%
ROA(3y)9.8%
ROA(5y)9.82%
ROE(3y)11.75%
ROE(5y)12.17%
ROIC(3y)9.7%
ROIC(5y)9.93%
ARBS.MI Yearly ROA, ROE, ROICARBS.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 10 20 30 40

1.3 Margins

ARBS's Profit Margin has declined in the last couple of years.
ARBS's Operating Margin has declined in the last couple of years.
In the last couple of years the Gross Margin of ARBS has declined.
Industry RankSector Rank
OM 32.36%
PM (TTM) 33.94%
GM 59.2%
OM growth 3Y-9.03%
OM growth 5Y-6.11%
PM growth 3Y-6.06%
PM growth 5Y-5.41%
GM growth 3Y-0.13%
GM growth 5Y-3.91%
ARBS.MI Yearly Profit, Operating, Gross MarginsARBS.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ARBS is still creating some value.
The number of shares outstanding for ARBS has been reduced compared to 1 year ago.
Compared to 5 years ago, ARBS has less shares outstanding
ARBS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ARBS.MI Yearly Shares OutstandingARBS.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
ARBS.MI Yearly Total Debt VS Total AssetsARBS.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

ARBS has an Altman-Z score of 6.62. This indicates that ARBS is financially healthy and has little risk of bankruptcy at the moment.
ARBS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.62
ROIC/WACC0.94
WACC9.68%
ARBS.MI Yearly LT Debt VS Equity VS FCFARBS.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.3 Liquidity

ARBS has a Current Ratio of 6.62. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 5.69 indicates that ARBS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.62
Quick Ratio 5.69
ARBS.MI Yearly Current Assets VS Current LiabilitesARBS.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ARBS have decreased strongly by -20.01% in the last year.
Measured over the past 5 years, ARBS shows a small growth in Earnings Per Share. The EPS has been growing by 1.27% on average per year.
The Revenue has decreased by -7.28% in the past year.
The Revenue has been growing slightly by 6.36% on average over the past years.
EPS 1Y (TTM)-20.01%
EPS 3Y0.1%
EPS 5Y1.27%
EPS Q2Q%117.87%
Revenue 1Y (TTM)-7.28%
Revenue growth 3Y5.4%
Revenue growth 5Y6.36%
Sales Q2Q%41.3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARBS.MI Yearly Revenue VS EstimatesARBS.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.18 indicates a reasonable valuation of ARBS.
ARBS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.29.
Industry RankSector Rank
PE 10.18
Fwd PE N/A
ARBS.MI Price Earnings VS Forward Price EarningsARBS.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.33
ARBS.MI Per share dataARBS.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)8.01
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.46%, ARBS is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.43, ARBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.46%

5.2 History

Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ARBS.MI Yearly Income VS Free CF VS DividendARBS.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 500K 1M

More info and screens

ARTERRA BIOSCIENCE SPA

BIT:ARBS (5/5/2025, 7:00:00 PM)

2.24

-0.12 (-5.08%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner ChangeN/A
Ins Owners44.27%
Ins Owner ChangeN/A
Market Cap14.92M
Analysts82.86
Price Target3.67 (63.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.46%
Yearly Dividend0.1
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10.18
Fwd PE N/A
P/S 3.77
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.41
EV/EBITDA 6.33
EPS(TTM)0.22
EY9.82%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.59
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)8.01
Profitability
Industry RankSector Rank
ROA 10.72%
ROE 12.68%
ROCE 11.28%
ROIC 9.1%
ROICexc 13.03%
ROICexgc 13.1%
OM 32.36%
PM (TTM) 33.94%
GM 59.2%
FCFM N/A
ROA(3y)9.8%
ROA(5y)9.82%
ROE(3y)11.75%
ROE(5y)12.17%
ROIC(3y)9.7%
ROIC(5y)9.93%
ROICexc(3y)18.46%
ROICexc(5y)20.3%
ROICexgc(3y)19.41%
ROICexgc(5y)22.9%
ROCE(3y)12.07%
ROCE(5y)12.38%
ROICexcg growth 3Y-24.37%
ROICexcg growth 5Y-19.2%
ROICexc growth 3Y-20.89%
ROICexc growth 5Y-18.65%
OM growth 3Y-9.03%
OM growth 5Y-6.11%
PM growth 3Y-6.06%
PM growth 5Y-5.41%
GM growth 3Y-0.13%
GM growth 5Y-3.91%
F-ScoreN/A
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.62
Quick Ratio 5.69
Altman-Z 6.62
F-ScoreN/A
WACC9.68%
ROIC/WACC0.94
Cap/Depr(3y)53.05%
Cap/Depr(5y)159.34%
Cap/Sales(3y)7.07%
Cap/Sales(5y)18.81%
Profit Quality(3y)83.42%
Profit Quality(5y)54.81%
High Growth Momentum
Growth
EPS 1Y (TTM)-20.01%
EPS 3Y0.1%
EPS 5Y1.27%
EPS Q2Q%117.87%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.28%
Revenue growth 3Y5.4%
Revenue growth 5Y6.36%
Sales Q2Q%41.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.83%
EBIT growth 3Y-4.11%
EBIT growth 5Y-0.14%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.24%
FCF growth 3Y113.22%
FCF growth 5Y18.33%
OCF growth 1Y-26.48%
OCF growth 3Y28.82%
OCF growth 5Y1.5%